Peptide profile
Cortagen
Pineal-derived peptide for brain and immunity · also known as Cortexin fragment, Ala-Glu-Asp-Pro, AEDP tetrapeptide
Compare Cortagen with other peptides →Summary
Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) derived from the pineal gland and developed within the Russian peptide bioregulator program. It is primarily studied for its neuroprotective and immunomodulatory properties, with research suggesting it may support cortical function, slow age-related neurological decline, and modulate immune responses. Most of its evidence base comes from Russian preclinical and limited clinical studies conducted in the 1980s–2000s.
- Typical dose
- 200–400 mcg/day (typically 1–2 mg per course)
- Half-life
- ~15–30 minutes (estimated; typical for short peptides)
- Route
- Subcutaneous, Intramuscular
- Cycle length
- 5–10 days, repeated 2–4 times per year
Mechanism
How it works
Cortagen acts as a peptide bioregulator, a class of short oligopeptides believed to interact with chromatin and regulate gene expression in a tissue-specific manner. It is thought to bind to DNA promoter regions in cortical and immune cells, upregulating the synthesis of proteins involved in neuronal survival, synaptic plasticity, and immune cell differentiation. Additionally, it may influence the production of neuropeptides and cytokines, modulating both the central nervous system and peripheral immune activity.
Reported in research
Benefits
- May support neuroprotection and slow age-associated cognitive decline
- Potential immunomodulatory effects, normalizing immune cell counts and activity
- May improve stress resilience and adaptation via regulation of cortical peptide signaling
- Studied for potential longevity-supporting effects consistent with other pineal-derived peptide bioregulators
Context, not a prescription
Dosing
- Typical range
- 200–400 mcg/day (typically 1–2 mg per course) (Subcutaneous, Intramuscular)
- Cycle length
- 5–10 days, repeated 2–4 times per year
- Half-life
- ~15–30 minutes (estimated; typical for short peptides)
Safety
Side effects & contraindications
Possible side effects
- Injection site redness or mild irritation
- Transient fatigue or drowsiness, particularly during initial dosing
- Mild headache reported in a small subset of users
- Possible transient immune activation symptoms (low-grade fever, malaise)
Contraindications
- Known hypersensitivity to any component of the formulation
- Autoimmune disorders where immune stimulation could be harmful
- Pregnancy and breastfeeding (insufficient safety data)
- Concurrent use of immunosuppressive therapies without medical supervision
Research information, not medical advice. Always consult a licensed clinician before considering any peptide.
In depth
Full profile
What it does
Users often report improved mental clarity, better stress tolerance, and a general sense of well-being. Some note improved sleep quality. Immune-related improvements (fewer colds, faster recovery) may emerge over a full course.
How it works
Imagine your cells are employees who have gotten lazy over time and forgotten their job descriptions. Cortagen is like a memo from management that reminds them exactly what tasks they're supposed to be doing — repairing themselves, communicating properly, and staying active.
After injection, Cortagen travels through the bloodstream and enters tissues where it can slip into cells and interact with DNA. It nudges certain genes to become more active, particularly those involved in keeping brain cells alive and keeping your immune system balanced. It doesn't override your body's systems — it gently nudges them back toward a healthier baseline.
What to expect
Most users report subtle effects within the first 3–5 days of a course, though cognitive and immune benefits may take 2–4 weeks to become noticeable.
- Days 1–3: Adjustment phase — you may feel slightly fatigued as your body responds. Injection site may be mildly red.
- Days 4–10: Many users begin to notice subtle improvements in focus, mood stability, and energy levels as the peptide course completes.
- Weeks 2–8 post-course: The intended 'bioregulator' effect is believed to persist for weeks to months after a short course, with gradual immune and cognitive benefits accumulating over repeated cycles.
Good to know
- Start with the lower end of the dosing range to assess personal tolerance
- Rotate injection sites to minimize local irritation
Staying safe
- Mild redness or soreness at the injection site
- Feeling slightly tired or sluggish during the first few days
Avoid if you have:
- Pregnant or breastfeeding women
- People with autoimmune conditions such as lupus or rheumatoid arthritis
- Anyone currently on immunosuppressant medications
Mechanism of action
Cortagen (Ala-Glu-Asp-Pro) is a tetrapeptide bioregulator theorized to interact directly with double-stranded DNA via electrostatic and hydrogen-bonding interactions with nucleotide base pairs. Research by Khavinson and colleagues suggests that such short peptides act as epigenetic modulators, capable of penetrating the nuclear envelope and binding to promoter sequences, thereby influencing transcription factor recruitment and chromatin remodeling. In neural tissue, Cortagen is proposed to upregulate expression of BDNF, NGF, and anti-apoptotic Bcl-2 family proteins, while in immune compartments it may modulate NF-κB signaling to normalize cytokine output (particularly IL-2, IL-6, and TNF-α). The proline residue at the C-terminus likely confers conformational rigidity that contributes to DNA-binding specificity and resistance to rapid enzymatic degradation relative to more flexible peptide sequences.
Following subcutaneous or intramuscular administration, Cortagen enters systemic circulation with rapid distribution kinetics typical of small peptides (estimated Vd consistent with extracellular fluid compartments). It crosses the blood-brain barrier to a limited degree, likely via adsorptive transcytosis. Tissue specificity is thought to arise not from receptor selectivity but from differential chromatin accessibility in target cell types — cortical neurons and immune progenitors exhibit open chromatin states at the relevant promoter motifs. Clearance occurs rapidly through renal filtration and peptidase activity, necessitating short but repeated dosing courses to achieve cumulative epigenetic effects.
Pharmacodynamics
Initial pharmacodynamic effects at the cellular level (altered gene transcription) may begin within hours of administration, but measurable clinical endpoints (cognitive performance metrics, CD4/CD8 ratios, NK cell activity) typically require 5–10 days of repeated dosing to show statistical separation from baseline in studied populations.
Physiological changes documented in preclinical models include: increased synaptic density markers in the cerebral cortex, normalization of corticosterone stress responses, improved spatial learning in aged rodents on Morris Water Maze paradigms, and restoration of age-depressed NK cell cytotoxicity. Human data are sparse but suggest trends toward improved psychometric performance and immune panel normalization in elderly cohorts studied in Russia.
Timeline
- Days 1–3: Peptide distributes to target tissues; early transcriptional changes in cortical and immune progenitor cells begin. Users may experience transient fatigue as the immune compartment responds.
- Days 4–10: Cumulative epigenetic effects consolidate; neurotrophic factor upregulation and immune cell activity normalization become more prominent. Subjective cognitive and mood improvements reported in this window.
- Weeks 2–8 post-course: The 'bioregulator hypothesis' posits that peptide-induced epigenetic changes persist well beyond circulating half-life. Animal models show sustained behavioral and immunological improvements for 4–8 weeks post-course. Repeat cycles 2–4 times annually are standard in Russian clinical protocols.
Comparisons
- Cortagen — effectiveness Moderate, safety Good, cost $$, Medium to use
- Epithalon — effectiveness Moderate, safety Good, cost $$, Medium to use
Adverse effects
Common:
- Injection site reactions: erythema, induration — generally self-limiting within 24–48 hours
- Transient fatigue attributed to immune activation or mild inflammatory signaling during initial treatment days
Rare:
- Transient low-grade fever (<38°C) consistent with mild cytokine release — reported anecdotally in <5% of users in available case series
Contraindications & risk mitigation
Contraindicated in:
- Patients with active autoimmune disease (SLE, RA, MS) due to risk of immune potentiation exacerbating disease activity
- Individuals on calcineurin inhibitors or other immunosuppressants where immune modulation could undermine therapeutic intent
- Patients with known pineal tumors or endocrine neoplasia pending further safety characterization
- Baseline immune panel (CBC with differential, CRP) before and after course to monitor for adverse immune activation
- Avoid co-administration with other immune-stimulating peptides (e.g., Thymalin, Thymogen) without medical supervision to prevent additive immune potentiation
- Use preservative-free bacteriostatic water for reconstitution and strict aseptic technique to minimize infection risk at injection site
Qué hace
Users often report improved mental clarity, better stress tolerance, and a general sense of well-being. Some note improved sleep quality. Immune-related improvements (fewer colds, faster recovery) may emerge over a full course.
Cómo funciona
Imagine your cells are employees who have gotten lazy over time and forgotten their job descriptions. Cortagen is like a memo from management that reminds them exactly what tasks they're supposed to be doing — repairing themselves, communicating properly, and staying active.
After injection, Cortagen travels through the bloodstream and enters tissues where it can slip into cells and interact with DNA. It nudges certain genes to become more active, particularly those involved in keeping brain cells alive and keeping your immune system balanced. It doesn't override your body's systems — it gently nudges them back toward a healthier baseline.
Qué esperar
Most users report subtle effects within the first 3–5 days of a course, though cognitive and immune benefits may take 2–4 weeks to become noticeable.
- Days 1–3: Adjustment phase — you may feel slightly fatigued as your body responds. Injection site may be mildly red.
- Days 4–10: Many users begin to notice subtle improvements in focus, mood stability, and energy levels as the peptide course completes.
- Weeks 2–8 post-course: The intended 'bioregulator' effect is believed to persist for weeks to months after a short course, with gradual immune and cognitive benefits accumulating over repeated cycles.
Bueno saber
- Start with the lower end of the dosing range to assess personal tolerance
- Rotate injection sites to minimize local irritation
Manteniéndose seguro
- Mild redness or soreness at the injection site
- Feeling slightly tired or sluggish during the first few days
Evitar si tienes:
- Pregnant or breastfeeding women
- People with autoimmune conditions such as lupus or rheumatoid arthritis
- Anyone currently on immunosuppressant medications
Mecanismo de acción
Cortagen (Ala-Glu-Asp-Pro) is a tetrapeptide bioregulator theorized to interact directly with double-stranded DNA via electrostatic and hydrogen-bonding interactions with nucleotide base pairs. Research by Khavinson and colleagues suggests that such short peptides act as epigenetic modulators, capable of penetrating the nuclear envelope and binding to promoter sequences, thereby influencing transcription factor recruitment and chromatin remodeling. In neural tissue, Cortagen is proposed to upregulate expression of BDNF, NGF, and anti-apoptotic Bcl-2 family proteins, while in immune compartments it may modulate NF-κB signaling to normalize cytokine output (particularly IL-2, IL-6, and TNF-α). The proline residue at the C-terminus likely confers conformational rigidity that contributes to DNA-binding specificity and resistance to rapid enzymatic degradation relative to more flexible peptide sequences.
Following subcutaneous or intramuscular administration, Cortagen enters systemic circulation with rapid distribution kinetics typical of small peptides (estimated Vd consistent with extracellular fluid compartments). It crosses the blood-brain barrier to a limited degree, likely via adsorptive transcytosis. Tissue specificity is thought to arise not from receptor selectivity but from differential chromatin accessibility in target cell types — cortical neurons and immune progenitors exhibit open chromatin states at the relevant promoter motifs. Clearance occurs rapidly through renal filtration and peptidase activity, necessitating short but repeated dosing courses to achieve cumulative epigenetic effects.
Farmacodinamia
Initial pharmacodynamic effects at the cellular level (altered gene transcription) may begin within hours of administration, but measurable clinical endpoints (cognitive performance metrics, CD4/CD8 ratios, NK cell activity) typically require 5–10 days of repeated dosing to show statistical separation from baseline in studied populations.
Physiological changes documented in preclinical models include: increased synaptic density markers in the cerebral cortex, normalization of corticosterone stress responses, improved spatial learning in aged rodents on Morris Water Maze paradigms, and restoration of age-depressed NK cell cytotoxicity. Human data are sparse but suggest trends toward improved psychometric performance and immune panel normalization in elderly cohorts studied in Russia.
Cronología
- Days 1–3: Peptide distributes to target tissues; early transcriptional changes in cortical and immune progenitor cells begin. Users may experience transient fatigue as the immune compartment responds.
- Days 4–10: Cumulative epigenetic effects consolidate; neurotrophic factor upregulation and immune cell activity normalization become more prominent. Subjective cognitive and mood improvements reported in this window.
- Weeks 2–8 post-course: The 'bioregulator hypothesis' posits that peptide-induced epigenetic changes persist well beyond circulating half-life. Animal models show sustained behavioral and immunological improvements for 4–8 weeks post-course. Repeat cycles 2–4 times annually are standard in Russian clinical protocols.
Comparaciones
- Cortagen — efectividad Moderate, seguridad Good, costo $$, Medium de usar
- Epithalon — efectividad Moderate, seguridad Good, costo $$, Medium de usar
Efectos adversos
Comunes:
- Injection site reactions: erythema, induration — generally self-limiting within 24–48 hours
- Transient fatigue attributed to immune activation or mild inflammatory signaling during initial treatment days
Raros:
- Transient low-grade fever (<38°C) consistent with mild cytokine release — reported anecdotally in <5% of users in available case series
Contraindicaciones y mitigación de riesgos
Contraindicado en:
- Patients with active autoimmune disease (SLE, RA, MS) due to risk of immune potentiation exacerbating disease activity
- Individuals on calcineurin inhibitors or other immunosuppressants where immune modulation could undermine therapeutic intent
- Patients with known pineal tumors or endocrine neoplasia pending further safety characterization
- Baseline immune panel (CBC with differential, CRP) before and after course to monitor for adverse immune activation
- Avoid co-administration with other immune-stimulating peptides (e.g., Thymalin, Thymogen) without medical supervision to prevent additive immune potentiation
- Use preservative-free bacteriostatic water for reconstitution and strict aseptic technique to minimize infection risk at injection site
Reference data
Specifications
- Molecular formula
- C16H24N4O9
- Molecular weight
- 432.38 g/mol
- Half-life
- ~15–30 minutes (estimated; typical for short peptides)
- Route
- Subcutaneous, Intramuscular
- Cycle length
- 5–10 days, repeated 2–4 times per year
- Storage
- Store lyophilized powder at 2–8°C (refrigerated). Protect from light and moisture. Reconstituted solution should be used within 24–48 hours and stored at 4°C. Do not freeze reconstituted peptide.
- Legal status
- Unscheduled research chemical in most Western countries; available as a peptide bioregulator supplement in Russia and Eastern Europe. Not FDA-approved for any indication.
FAQ
Common questions
What is the evidence basis for Cortagen's DNA-binding mechanism?
Khavinson et al. published a series of studies using molecular modeling and in vitro chromatin binding assays (published in Bulletin of Experimental Biology and Medicine and Advances in Gerontology) demonstrating that short tetrapeptides including AEDP show sequence-selective binding to double-stranded DNA. Crystal structure confirmation remains limited, and Western independent replication of these specific claims is minimal, representing a significant gap in the evidence base.
How does Cortagen compare mechanistically to Epithalon?
Epithalon (AEDG) differs by a single C-terminal residue (Gly vs Pro) and is more extensively studied, particularly for telomerase activation via TERT promoter modulation. Cortagen's proposed targets appear more weighted toward cortical neurotrophic and immune gene networks, though significant mechanistic overlap is expected given the structural similarity. No head-to-head mechanistic comparison has been published.
What is the evidence level?
This compound is classified as Animal data. Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.
Research
Research & sources
Current evidence for Cortagen is rated as Animal data. Research is based primarily on animal models.
- 1. Khavinson VKh et al. — Peptide regulation of gene expression and protein synthesis in bronchial epithelium (2003) — Bulletin of Experimental Biology and Medicine, 35(4)
- 2. Khavinson VKh, Morozov VG — Peptides of pineal gland and thymus prolong human life (2003) — Neuroendocrinology Letters, 24(3-4):233-240
- 3. Anisimov VN et al. — Effect of Epithalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice (2003) — Biogerontology, 4(4):193-202
Explore